Media headlines about Vanda Pharmaceuticals (NASDAQ:VNDA) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vanda Pharmaceuticals earned a news impact score of 0.13 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 38 out of 100, meaning that recent news coverage is unlikely to have an impact on the company’s share price in the near future.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Critical Comparison: Vanda Pharmaceuticals (VNDA) & bluebird bio (BLUE) (americanbankingnews.com)
- Zacks: Brokerages Anticipate Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to Announce -$0.21 EPS (americanbankingnews.com)
- Verastem, Inc. (VSTM) registers a price change of -2.72% while Vanda Pharmaceuticals Inc. (VNDA) finishes with a … – Stocks Gallery (stocksgallery.com)
- MAMA Cross Spotted in Vanda Pharmaceuticals Inc (VNDA) Shares – Evergreen Caller (evergreencaller.com)
- Needle Action Activity Spotted in Vanda Pharmaceuticals Inc (VNDA) – Stock Press Daily (stockpressdaily.com)
Vanda Pharmaceuticals (NASDAQ:VNDA) traded down 0.32% on Friday, reaching $15.75. The company had a trading volume of 272,841 shares. Vanda Pharmaceuticals has a 52-week low of $11.41 and a 52-week high of $18.00. The company’s market capitalization is $701.69 million. The company’s 50-day moving average is $15.78 and its 200-day moving average is $14.58.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by $0.04. Vanda Pharmaceuticals had a negative net margin of 8.85% and a negative return on equity of 10.42%. The business had revenue of $37.42 million during the quarter, compared to analysts’ expectations of $38.35 million. Equities analysts anticipate that Vanda Pharmaceuticals will post ($0.70) EPS for the current fiscal year.
VNDA has been the topic of several recent research reports. Piper Jaffray Companies restated an “overweight” rating and issued a $23.00 price objective on shares of Vanda Pharmaceuticals in a research report on Tuesday, June 27th. HC Wainwright initiated coverage on Vanda Pharmaceuticals in a research report on Friday, May 26th. They set a “buy” rating and a $18.00 target price on the stock. CIBC reiterated an “outperform” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a research report on Wednesday, April 12th. Zacks Investment Research upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, June 14th. Finally, TheStreet upgraded Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Friday, May 12th. One analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $21.22.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.